Clinical trial
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus…
NCT00117884 · Takeda, Industry · Terminated
Key facts
| NCT number | NCT00117884 |
|---|---|
| Title | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. |
| Official title | A Randomized, Double-blind, Placebo-Controlled, Dose Response Study to Evaluate 851B Gel Delivered Intravaginally Twice a Week for Two, Three-Week Cycles in Women Who Are Positive For High-Risk Genotypes of Human Papillomavirus and Have Mild Cytological Abnormalities |
| Lead sponsor | Takeda, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Papillomavirus Infections |
| Intervention type | Drug |
| Interventions | 851B |
| Enrollment | 240 |
| Start date | Apr 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jul 11, 2005 |
| Last update posted | Aug 19, 2016 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: